- Trials with a EudraCT protocol (79)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
79 result(s) found for: Hypercalcemia.
Displaying page 2 of 4.
EudraCT Number: 2012-000321-41 | Sponsor Protocol Number: ALENDROHNP2011 | Start Date*: 2012-04-18 | |||||||||||
Sponsor Name:FUNDACION HOSPITAL NACIONAL DE PARAPLEJICOS PARA LA INVESTIGACIÓN Y LA INTEGRACIÓN | |||||||||||||
Full Title: PREVENTIVE TREATMENT OF BONE MASS LOSS WITH ALENDRONATE AND CALCIFEDIOL IN PATIENTS WITH ACUTE SPINAL CORD INJURY | |||||||||||||
Medical condition: Preventing loss of bone density in patients with spinal cord injury of traumatic etiology complete during the first year of evolution of the lesion. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002606-39 | Sponsor Protocol Number: 20162020 | Start Date*: 2016-11-09 | |||||||||||
Sponsor Name:Nemocnice Na Homolce | |||||||||||||
Full Title: Resurgence in sternotomy fortified by vitamin D supplementation in cardiac surgery | |||||||||||||
Medical condition: sternotomy healing | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2023-000010-18 | Sponsor Protocol Number: WATERLAND | Start Date*: 2023-03-23 | |||||||||||
Sponsor Name:Enrique de Madaria | |||||||||||||
Full Title: Normal saline versus lactated Ringer’s solution for acute pancreatitis resuscitation, an open-label multicenter randomized controlled trial: the WATERLAND trial | |||||||||||||
Medical condition: Acute pancreatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021665-68 | Sponsor Protocol Number: Citrasate01 | Start Date*: 2010-10-06 | ||||||||||||||||
Sponsor Name:University Hospital Antwerp | ||||||||||||||||||
Full Title: Comparison of Slow Efficiency dialysis (SLEDD) with Unfractionated Heparin versus Citrasate in Critically Ill Patients | ||||||||||||||||||
Medical condition: To compare the feasability, safety and efficacy of Sustained Slow Efficiency Dialys (SLEDD) using regional anticoagulation with Citrasate compared to systemic anticoagulation with Unfractionated He... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005683-21 | Sponsor Protocol Number: ENM-EA-030 | Start Date*: 2012-10-09 |
Sponsor Name:Medizinische Universität Graz | ||
Full Title: Effects of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial | ||
Medical condition: Primary hyperparathyroidism | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-004087-31 | Sponsor Protocol Number: CLBH589B2203 | Start Date*: 2007-02-22 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A Phase II Study Of Oral LBH589 In Adult Patients With Multiple Myeloma Who Have Received At Least Two Prior Lines Of Therapy And Whose Disease Is Refractory To The Most Recent Line Of Therapy | |||||||||||||
Medical condition: Patients with relapsed multiple myeloma who have received at least two prior lines of therapy and whose disease is refractory to the most recent line of therapy. Prior therapy must have included bo... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) IT (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001709-27 | Sponsor Protocol Number: 26866138MMY2038 | Start Date*: 2006-09-25 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of Velcade® when added to Adriamycin-Dexamethasone Treatment versus Vincristine-Adriamycin-D... | |||||||||||||
Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) DE (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005819-26 | Sponsor Protocol Number: 26866138-MMY-2036 | Start Date*: 2006-05-19 | |||||||||||
Sponsor Name:Janssen-Cilag EMEA Medical Affairs | |||||||||||||
Full Title: A Phase II, Open-Label Trial Using VELCADE for Re-Treatment of Multiple Myeloma Subjects Following an Initial Response to VELCADE | |||||||||||||
Medical condition: multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) PT (Completed) ES (Completed) IT (Completed) GR (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004815-33 | Sponsor Protocol Number: TransCon_PTH_TCP-201 | Start Date*: 2019-09-27 | |||||||||||
Sponsor Name:Ascendis Pharma Bone Diseases A/S | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial with an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administ... | |||||||||||||
Medical condition: Hypoparathyroidism (HP) in Adults | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015507-52 | Sponsor Protocol Number: CLBH589D2308 | Start Date*: 2009-11-13 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma | |||||||||||||
Medical condition: Multiple Myeloma (MM), relapsed or relapsed-and-refractory | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) DE (Completed) NL (Completed) BE (Completed) DK (Completed) IT (Completed) FR (Completed) ES (Completed) CZ (Completed) PL (Completed) GB (Completed) AT (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002122-67 | Sponsor Protocol Number: 1211 | Start Date*: 2013-12-05 | |||||||||||
Sponsor Name:EORTC | |||||||||||||
Full Title: Phase II randomized comparative trial of TAK-700 (Orteronel) versus bicalutamide in metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castration. | |||||||||||||
Medical condition: metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: BE (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002948-40 | Sponsor Protocol Number: GEM-CESAR | Start Date*: 2015-03-03 | |||||||||||
Sponsor Name:Fundación PETHEMA | |||||||||||||
Full Title: A phase II multicenter study of carfilzomib, lenalidomide and dexamethasone (KRd) plus high-dose therapy with melphalan-200 and autologous stem cell transplantation, followed by consolidation with ... | |||||||||||||
Medical condition: Smoldering multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006065-16 | Sponsor Protocol Number: FP-006-IM | Start Date*: 2007-03-19 | |||||||||||
Sponsor Name:Nycomed Danmark ApS | |||||||||||||
Full Title: A 24-week, international, multi centre, randomised, open label, parallel group, phase IV clinical trial investigating changes in bone formation markers in postmenopausal women with primary osteopor... | |||||||||||||
Medical condition: Primary postmenopausal osteoporosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: AT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002460-13 | Sponsor Protocol Number: VITDALIZE | Start Date*: 2017-01-03 |
Sponsor Name:Medical University of Graz | ||
Full Title: Effect of high-dose vitamin D3 on 28-day mortality in adult critically ill patients with severe vitamin D deficiency: a multicenter, placebo-controlled double-blind phase III RCT | ||
Medical condition: Adult critically ill patients with severe vitamin D deficiency | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001189-87 | Sponsor Protocol Number: SAKK96/12 | Start Date*: 2017-07-18 | ||||||||||||||||
Sponsor Name:Swiss Group for Clinical Cancer Research | ||||||||||||||||||
Full Title: Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks versus every 12 Weeks - A Non-Inferiority Phase III trial | ||||||||||||||||||
Medical condition: Bone metastases from castration resistant prostate cancer or from breast cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) AT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002992-16 | Sponsor Protocol Number: EMN17/54767414MMY3014 | Start Date*: 2019-01-30 | |||||||||||
Sponsor Name:European Myeloma Network (EMN) | |||||||||||||
Full Title: A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Previously Untreated Multiple... | |||||||||||||
Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) GR (Trial now transitioned) NO (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000849-38 | Sponsor Protocol Number: CRAD001C2223 | Start Date*: 2005-08-03 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A Phase 3, randomized, double-blind, placebo-controlled multi-center study of RAD001 in combination with letrozole (Femara®) to investigate the value of adding RAD001 to letrozole as a first-line t... | ||
Medical condition: The treatment of advanced breast cancer aims at reducing tumor size, slowing progression and metastasis and reducing complications such as fatigue, bone fracture and hypercalcemia. Women with tumor... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-000087-15 | Sponsor Protocol Number: CRd | Start Date*: 2012-03-30 |
Sponsor Name:FONDAZIONE NEOPLASIE SANGUE ONLUS | ||
Full Title: A PHASE II, MULTI-CENTER, OPEN LABEL STUDY OF CYCLOPHOSPHAMIDE IN MULTIPLE MYELOMA PATIENTS WITH BIOCHEMICAL PROGRESSION DURING LENALIDOMIDE-DEXAMETHASONE TREATMENT FOR RELAPSED/REFRACTORY MULTIPLE... | ||
Medical condition: RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002659-28 | Sponsor Protocol Number: 20160428 | Start Date*: 2017-11-10 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: An open-label, Randomized, Single-dose, 2-Period, "-Treatment Crossover Study to Assess the Bioequivalence of Cinacalcet Capsule (Administered as Six of the 5 mg Cinacalcet Capsules) with 30 mg Com... | |||||||||||||
Medical condition: Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and for the treatment of hypercalcemia in patients with parathyroid carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004347-12 | Sponsor Protocol Number: ICT-10 | Start Date*: 2016-03-05 | |||||||||||
Sponsor Name:Hybrigenics SA | |||||||||||||
Full Title: Exploratory Study of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study | |||||||||||||
Medical condition: Residual disease in Chronic Myeloid Leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
